122 related articles for article (PubMed ID: 9092852)
21. Development of a syngenic brain-tumor model resistant to chloroethyl-nitrosourea using a methylguanine DNA methyltransferase cDNA.
Manome Y; Watanabe M; Futaki K; Ishiguro H; Iwagami S; Noda K; Dobashi H; Ochiai Y; Ohara Y; Sanuki K; Kunieda T; Ohno T
Anticancer Res; 1999; 19(6B):5313-8. PubMed ID: 10697554
[TBL] [Abstract][Full Text] [Related]
22. The 9L rat brain tumor model for pre-clinical investigation of radiation-chemotherapy interactions.
Kimler BF
J Neurooncol; 1994; 20(2):103-9. PubMed ID: 7528789
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of intralesionally administered cisplatin-impregnated biodegradable polymer for the treatment of 9L gliosarcoma in the rat.
Lillehei KO; Kong Q; Withrow SJ; Kleinschmidt-DeMasters B
Neurosurgery; 1996 Dec; 39(6):1191-7; discussion 1197-9. PubMed ID: 8938774
[TBL] [Abstract][Full Text] [Related]
24. Sodium magnetic resonance imaging of chemotherapeutic response in a rat glioma.
Schepkin VD; Ross BD; Chenevert TL; Rehemtulla A; Sharma S; Kumar M; Stojanovska J
Magn Reson Med; 2005 Jan; 53(1):85-92. PubMed ID: 15690506
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of (E)-2'-deoxy-2'-(fluoromethylene)cytidine on the 9L rat brain tumor model using MRI.
Ross BD; Chenevert TL; Garwood M; Kim B; Stegman LD; Ben-Yoseph O; Zwolshen J; Rehemtulla A; Sunkara PS
NMR Biomed; 2003 Apr; 16(2):67-76. PubMed ID: 12730947
[TBL] [Abstract][Full Text] [Related]
26. Local delivery of interleukin-2 and adriamycin is synergistic in the treatment of experimental malignant glioma.
Hsu W; Lesniak MS; Tyler B; Brem H
J Neurooncol; 2005 Sep; 74(2):135-40. PubMed ID: 16193383
[TBL] [Abstract][Full Text] [Related]
27. [Cancer chemo-endocrine therapy and its cell biological basis].
Nishiya I
Hum Cell; 1998 Sep; 11(3):109-14. PubMed ID: 10086273
[TBL] [Abstract][Full Text] [Related]
28. Influence of an anti-angiogenic treatment on 9L gliosarcoma: oxygenation and response to cytotoxic therapy.
Teicher BA; Holden SA; Ara G; Dupuis NP; Liu F; Yuan J; Ikebe M; Kakeji Y
Int J Cancer; 1995 May; 61(5):732-7. PubMed ID: 7768649
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic effects of photosensitizers in combination with laser and ACNU on an in vivo or in vitro model of cerebral glioma.
Chen KT; Hau DM; You JS; Pan HC; Wong RW
Chin Med J (Engl); 1995 Feb; 108(2):98-104. PubMed ID: 7774398
[TBL] [Abstract][Full Text] [Related]
30. New prodrug activation gene therapy for cancer using cytochrome P450 4B1 and 2-aminoanthracene/4-ipomeanol.
Rainov NG; Dobberstein KU; Sena-Esteves M; Herrlinger U; Kramm CM; Philpot RM; Hilton J; Chiocca EA; Breakefield XO
Hum Gene Ther; 1998 Jun; 9(9):1261-73. PubMed ID: 9650611
[TBL] [Abstract][Full Text] [Related]
31. Proton and sodium MRI assessment of emerging tumor chemotherapeutic resistance.
Schepkin VD; Lee KC; Kuszpit K; Muthuswami M; Johnson TD; Chenevert TL; Rehemtulla A; Ross BD
NMR Biomed; 2006 Dec; 19(8):1035-42. PubMed ID: 16894643
[TBL] [Abstract][Full Text] [Related]
32. Induction of immunity in peripheral tissues combined with intracerebral transplantation of interleukin-2-producing cells eliminates established brain tumors.
Iwadate Y; Yamaura A; Sato Y; Sakiyama S; Tagawa M
Cancer Res; 2001 Dec; 61(24):8769-74. PubMed ID: 11751397
[TBL] [Abstract][Full Text] [Related]
33. The role of minocycline in the treatment of intracranial 9L glioma.
Weingart JD; Sipos EP; Brem H
J Neurosurg; 1995 Apr; 82(4):635-40. PubMed ID: 7897527
[TBL] [Abstract][Full Text] [Related]
34. Mechanism of action of lonidamine in the 9L brain tumor model involves inhibition of lactate efflux and intracellular acidification.
Ben-Yoseph O; Lyons JC; Song CW; Ross BD
J Neurooncol; 1998 Jan; 36(2):149-57. PubMed ID: 9525814
[TBL] [Abstract][Full Text] [Related]
35. Sensitivity of 9L gliosarcomas to photodynamic therapy.
Chopp M; Dereski MO; Madigan L; Jiang F; Logie B
Radiat Res; 1996 Oct; 146(4):461-5. PubMed ID: 8927718
[TBL] [Abstract][Full Text] [Related]
36. [Flow cytometric studies of brain tumors--5: New sensitivity test of antineoplastic agents for brain tumors and its clinical application].
Kawakami K; Kawamoto K; Oka N; Kawamura Y; Matsumura H; Ito T; Ohyama A
No Shinkei Geka; 1986 Apr; 14(5):627-34. PubMed ID: 2425281
[TBL] [Abstract][Full Text] [Related]
37. Measurement of sister chromatid exchange induction in intracerebral brain tumors as a method for evaluation of therapeutic drug combinations.
Bodell WJ
Anticancer Res; 2000; 20(5A):3099-103. PubMed ID: 11062728
[TBL] [Abstract][Full Text] [Related]
38. Antiangiogenic effects of dexamethasone in 9L gliosarcoma assessed by MRI cerebral blood volume maps.
Badruddoja MA; Krouwer HG; Rand SD; Rebro KJ; Pathak AP; Schmainda KM
Neuro Oncol; 2003 Oct; 5(4):235-43. PubMed ID: 14565159
[TBL] [Abstract][Full Text] [Related]
39. [Studies on the mechanism of ACNU resistance in sublines of rat C6 glioma and 9L gliosarcoma in vitro].
Yoshida T; Shimizu K; Ushio Y; Hayakawa T; Kato A; Mogami H; Sakamoto Y
No Shinkei Geka; 1986 Oct; 14(11):1299-304. PubMed ID: 3468375
[TBL] [Abstract][Full Text] [Related]
40. [Local chemotherapy for malignant brain tumors using methotrexate-containing fibrin glue].
Hirakawa W; Kadota K; Asakura T; Niiro M; Yokoyama S; Hirano H; Yatsushiro K; Kubota Y; Shimodozono Y
Gan To Kagaku Ryoho; 1995 May; 22(6):805-9. PubMed ID: 7755389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
